Skip to main content
. 2021 Sep 9;9(4):100581. doi: 10.1016/j.hjdsi.2021.100581

Fig. 2.

Fig. 2

Laboratory and clinical outcome data presented to key stakeholders. (A–B) Laboratory trends in eleven COVID-19 patients after tocilizumab treatment. Medians (blue lines), interquartile ranges (IQR, blue shading), and reference ranges (dashed red lines). (C–D) Oxygen requirements and temperature trends, displayed using locally estimated scatterplot smoothing (orange lines). Patient #6 was treated with two doses of tocilizumab; time 0 refers to the time of initial administration.